New issues on measurement of B-type natriuretic peptides

Aldo Clerico, Martina Zaninotto, Claudio Passino, Mario Plebani
  • Clinical Chemistry and Laboratory Medicine (CCLM), November 2017, De Gruyter
  • DOI: 10.1515/cclm-2017-0433

What is it about?

Clinicians should accurately consider both the clinical setting of patients and the analytical characteristics of immunoassays in order to correctly interpret the variations of natriuretic peptides measured by commercially available laboratory methods, especially in patients treated with the new drug class of angiotensin receptor-neprilysin inhibitors (ARNi).

Read Publication

http://dx.doi.org/10.1515/cclm-2017-0433

The following have contributed to this page: Aldo Clerico